(Summary description)Suzhou, April 3, 2022 - Kintor Pharmaceutical Limited (Kintor Pharma, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced two poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2022, including proxalutamide to treat COVID-19 and a c-Myc Degrader to treat blood cancer and small cell lung cancers (SCLC). This year's AACR annual meeting will be held in the city of New Orleans, United States, on April 8-13, 2022.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2022-04-03 18:43
- Views:
Suzhou, April 3, 2022 - Kintor Pharmaceutical Limited (Kintor Pharma, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced two poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2022, including proxalutamide to treat COVID-19 and a c-Myc Degrader to treat blood cancer and small cell lung cancers (SCLC). This year's AACR annual meeting will be held in the city of New Orleans, United States, on April 8-13, 2022.
■ E-Poster
Mechanisms of action (MOA) for proxalutamide, an androgen receptor (AR) antagonist, for the treatment of mild, moderate and severe COVID-19 patients
Abstract#: 5274
Session Title: COVID-19 and Cancer
Session Time: April 8, 2022, 12:00 PM - 1:00 PM
Abstract Link: https://www.abstractsonline.com/pp8/#!/10517/presentation/18533
Discovery and evaluation of GT19630, a c-Myc/GSPT1 cereblon E3 ligase modulator(CELMoD) , for targeting Myc-driven blood cancers and small cell lung cancers(SCLC)
Abstract#: 5479
Session Title: Small Molecule Therapeutic Agents
Session Time: April 8, 2022, 12:00 PM - 1:00 PM
Abstract Link: https://www.abstractsonline.com/pp8/#!/10517/presentation/18624
Please refer to the website of AACR for more details.